School of Medicine
Showing 891-900 of 1,544 Results
-
Devin Malloy McCauley
Postdoctoral Scholar, Adolescent Medicine
BioDevin McCauley earned his PhD in Human Development and Family Studies from The Pennsylvania State University in 2021, where his research applied intensive longitudinal methods and time-varying effect modeling to investigate family, school, and peer influences on adolescent mental health and well-being. A second focus of his research applies a developmental framework in study of adolescent e-cigarette use. He is particularly interested in identifying sociodemographic (e.g., race/ethnicity, sexual identity) disparities in risk factors for e-cigarette use. His long-term goal is to inform, develop, and evaluate family and school-based prevention programs which support healthy adolescent development and address health disparities related to e-cigarette use.
-
Sean McGhee
Clinical Professor, Pediatrics - Immunology
Current Research and Scholarly InterestsBioinformatics
-
Mark McGovern
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences) and, by courtesy, of Pediatrics
BioDr. Mark McGovern is a Professor and the Associate Chair of Translation and Implementation Research in the Department of Psychiatry & Behavioral Sciences and, by courtesy, the Department of Medicine at Stanford University School of Medicine.
Most people who need health care do not receive it. And of those who do, wide variation exists in access to care and the quality of the care they receive in health care systems, both private and public. Dr. McGovern is a leader in using rigorous methods of implementation science to close these gaps in health care delivery.
His mission is to get the best health care possible to the people who need it the most.
Dr. McGovern's primary focus is the implementation and sustainment of evidence-based interventions and guideline adherent care in public and private health care systems and organizations. Within the hub of the Stanford Center for Dissemination and Implementation (CDI) which he directs, Dr. McGovern is the Principal Investigator (PI) and leads three national implementation research and practice centers: The Center for Dissemination and Implementation At Stanford (C-DIAS); The Research Adoption Support Center (RASC); and, the Mental Health Technology Transfer Center Network Coordinating Center (MHTTC). The 3 centers are federally-funded, respectively by the National Institute on Drug Abuse (P50DA05402), the National Institutes of Health Healing Addiction Long Term (HEAL) initiative (U2CDA057717), and the US Department of Health and Human Services Substance Use and Mental Health Services Administration (H79SM081726). Dr. McGovern is also the PI on a multi-site adaptive implementation trial across a state system of care, which aims to integrate addiction medications for persons with opioid use disorder who are receiving services in specialty or primary care organizations (R01DA052975). In addition, he addresses implementation challenges in federally-qualified health centers (FQHCs) across the State of California, in the Stanford Division of Primary Care and Population Health, and in specialty addiction and mental health treatment organizations nationwide. He leads, facilitates and/or actively engages networks advancing implementation science in health, including the NIDA Clinical Trials Network Translation & Implementation Special Interest Group, the NIDA Clinical Trials Western States Node Translation & Implementation Workgroup, the Stanford University Network for Dissemination & Implementation Research (SUNDIR), the VA Palo Alto HSR&D Center for Innovation to Implementation, and the Stanford Medicine Center for Improvement. He is on the Core Faculty of the National Institute of Mental Health Implementation Research Institute at the Washington University in St. Louis. Dr. McGovern is a collaborator on multiple projects as a co-investigator, consultant, or advisory board member. He is a mentor to numerous individuals across the country and at Stanford, from university undergraduates to mid-career faculty and clinical administrators at academic institutions and health care systems nationwide. -
Rebecca Mckenzie
Clinical Assistant Professor, Pediatrics - General Pediatrics
Current Research and Scholarly InterestsPediatric liver transplant, outcomes, adherence, transition, liver failure
-
Peter Meaney
Clinical Professor, Pediatrics - Critical Care
Current Research and Scholarly InterestsDr. Meaney is a nationally and internationally recognized pediatric resuscitation scientist, and his current focus is on improving care for seriously ill children at the community clinic and district hospital level in low and middle income countries. Dr Meaney seeks to conduct the necessary research to pioneer, implement and evaluate innovative yet relevant and practical solutions to improve the quality of care for seriously ill or injured children worldwide.
-
Rishi Mediratta
Clinical Associate Professor, Pediatrics
Current Research and Scholarly InterestsI have developed a new promising neonatal mortality prediction score at the University of Gondar Neonatal Intensive Care Unit (NICU) in Gondar, Ethiopia. The score predicts approximately 84% of neonatal deaths in the NICU using clinical variables. I have a dataset over 800 NICU admissions in Gondar. I am recruiting scholars who are interested in conducting clinical and epidemiological research to validate, refine, and implement the mortality score to reduce neonatal mortality in Ethiopia.
-
Eric Meffre
Professor of Medicine (Immunology and Rheumatology)
BioDr. Meffre obtained his PhD in Immunology from the Université d’Aix-Marseille in France before he moved to the USA as a postdoc fellow in the laboratory of Dr. Michel Nussenzweig at The Rockefeller University in New York City. He became an assistant professor at Cornell University in 2003 before being recruited at Yale University as associate professor in 2009. He was tenured at Yale in 2014 before he joined the Department of Medicine/Division of Immunology and Rheumatology at Stanford University as a tenured full professor in 2022.
Dr. Meffre’s work focuses on the etiology of autoimmune syndromes and the roles played by B cells in these diseases. His group characterized the abnormal selection of developing autoreactive B cells in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), multiple sclerosis (MS) and Sjögren’s syndrome, resulting in large numbers of autoreactive naïve B cells accumulating in the patient’s blood. Hence, these autoreactive B cells may present self-antigens to T cells and initiate autoimmune diseases. These early B cell tolerance defects are likely primary to these autoimmune diseases and may result from genetic factors such as the 1858T PTPN22 allele that segregates with RA, SLE and T1D and correlate with an impaired removal of developing autoreactive B cells.
His research goals also consist in characterizing the molecules and pathways involved in the establishment of B cell tolerance and the removal of developing autoreactive B cells generated by random V(D)J recombination through the investigation of rare patients with primary immunodeficiency (PID) enrolled through an international network. Alteration of B cell receptor (BCR) or Toll-like receptor (TLR) signaling in PID patients results in a defective central B cell tolerance and a failure to counterselect developing autoreactive B cells in the bone marrow. In contrast, functional and suppressive regulatory T cells play a key role in preventing the accumulation of autoreactive clones in the mature naïve B cell compartment. The recent development of humanized mouse models recapitulating early B cell tolerance checkpoints and their defects in autoimmune settings allow further in-depth investigation of tolerance mechanisms and the development of novel approaches to restore defective central and peripheral B cell tolerance checkpoints and thwart autoimmunity.
